IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.
Phase 2 other active
Quick answer
IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract. for Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract is a Phase 2 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract
- Phase
- Phase 2
- Modality
- other
- Status
- active